Enlitic Partners with NXC Imaging to Help Integrate Medical AI into Clinical Practice in the U.S.
–Leading Medical Imaging Provider to Streamline Distribution of Comprehensive Clinical AI Platform in Several Midwestern States–
SAN FRANCISCO, November, 2019 – Enlitic, Inc., a leading developer of artificial intelligence software designed to help doctors diagnose patient conditions more quickly and more accurately, announced today that it has signed an exclusive distribution partnership with NXC Imaging, the leading medical imaging distributor in the U.S. (500 hospitals, 15 million patients) Through the agreement, NXC becomes the exclusive distributor of Enlitic’s comprehensive, AI-powered software platform across Minnesota, The Dakotas, Wisconsin and parts of Iowa, Michigan, and Montana. As a result, Enlitic will have deep penetration into hospitals and integrated delivery networks (IDNs) across the Midwestern U.S., a key distribution pipeline, setting the stage for mass commercialization throughout the country. Enlitic will debut its platform in December at RSNA 2019 and has set its sights on global market deployment in 2020.
Enlitic’s deep learning models have demonstrated amazing potential to improve radiologist efficiency and accuracy in the interpretation of diagnostic images. In a clinical validation study from 2017, radiologists with support from Enlitic, were found to interpret X-rays of the extremities 21% faster with an 11% higher true positive rate and a 9% reduction in false positives. Enlitic has since extended this functionality to cover the majority of findings in X-ray across the entire body, with the goal of covering the majority of CT and MRI in coming years.
Enlitic’s partnership with NXC Imaging adds to the company’s global partnership roster of leading healthcare and technology companies, including Capitol Health, a leading Australian healthcare provider; Marubeni Corporation, a Japan-based global conglomerate; Konica Minolta, a leading multi-national technology company also based in Japan; and Select HealthCare, a developer, owner, and operator of world-class cancer centers across the U.S.
“The team at NXC has built and cultivated exceptionally strong and enduring relationships with hospitals and IDNs in the Midwest over the past 50-plus years, making them an ideal partner as we look forward to wider commercialization in 2020,” said Kevin Lyman, Enlitic’s Chief Executive Officer. “I am highly confident that our partnership will accelerate our common mission to improve patient outcomes with best-in-class technology and service.”
“Enlitic is developing medical AI software that is truly ground-breaking and we are very excited about the opportunity to introduce their technology to patients in our communities,” said Bruce Zeilinger, NXC’s Chief Executive Officer. “Enlitic’s platform will integrate seamlessly into any existing health system infrastructure making it a fantastic addition to our comprehensive portfolio of capital imaging equipment.”
About NXC Imaging
NXC is an employee owned company in business since 1964 with 95 entrepreneurial employees and is an exclusive partner and service provider of capital medical equipment – MRI, CT, Vascular, Ultrasound, X-Ray, 3D Mammography and Bone Densitometry throughout the United States. NXC represents premier diagnostic imaging manufactures: Canon, Hologic and Carestream. Recently, NXC has also partnered with Medicom to build a national Health Information Exchange and dramatically reduce unnecessary re-imaging and re-admissions. NXC has consistently been recognized as a Top Workplace in Minnesota over the last decade.
Named one of the world’s “50 Smartest Companies” by MIT Technology Review, Enlitic is a pioneer in medical deep learning, building a best-in-class platform that bridges human and artificial intelligence to save time, money, and ultimately, lives. The company’s team of practicing radiologists, data scientists, and software engineers analyze a vast stream of healthcare data –– including millions of clinical cases from cross-sector healthcare partners –– to improve diagnostic accuracy, speed, and patient outcomes, as well as to accelerate pharmaceutical research and drug trials. Enlitic is based in San Francisco and has offices in New York and Sydney, Australia. Find out more at enlitic.com, and follow the company on Twitter, and LinkedIn.
# # #